Li Hui-Min, Li Feng-Chao, Zhang Yi, Guo Jia-Chen, Deng Wei, Jiang Gui-Hua, Lian Yan
Key Laboratory of Standardization of Chinese Medicine, State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137, China.
School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine Chengdu 611137, China.
Zhongguo Zhong Yao Za Zhi. 2022 Apr;47(8):2257-2265. doi: 10.19540/j.cnki.cjcmm.20220115.101.
Through literature research and standard retrieval, Corydalis-derived medicinal materials, the origins, and related standards were summarized. Finally, 27 medicinal materials were screened out, involving 71 species(varieties). Among them, only 11 are recorded in Chinese Pharmacopoeia(2020), National Standard for Chinese Patent Drugs·Tibetan Medicine, Tibetan Medicine Standards, and other local standards, including Corydalis Bungeanae Herba and Corydalis Herba. The names and original plants of the medicinal materials are different in different standards, and the phenomena of "same medicinal material with different names" and "same name for different medicinal materials" are prominent. Most standards only include the traits, microscopic identification, and physico-chemical property identification, with unsound quality criteria. Thus, efforts should be made to strengthen the sorting of Corydalis medicinal plants, herbal textual research, and investigation of the resources and utilization. Moreover, via modern techniques, the chemical components and medicinal material basis of different original plants should be explored and sound quality standards should be established to improve the safety and quality of Corydalis-derived medicinal materials. Summarizing Corydalis medicinal plants, Corydalis-derived medicinal materials, and related standards, this study is expected to provide a reference for the standard formulation, quality evaluation, expansion of drug sources, and rational development and utilization of Corydalis resources.
通过文献研究和标准检索,对紫堇属药用植物、来源及相关标准进行了总结。最终筛选出27种药用植物,涉及71个种(变种)。其中,仅11种被《中国药典》(2020年版)、《中成药国家标准·藏药》、《藏药标准》等地方标准收录,包括地锦草和紫堇全草。不同标准中,药用植物的名称及原植物存在差异,“同名异物”和“同物异名”现象突出。多数标准仅包含性状、显微鉴别和理化性质鉴别,质量标准不完善。因此,应加强紫堇属药用植物的整理、本草考证以及资源与利用调查。此外,通过现代技术,探索不同原植物的化学成分和药材基础,建立完善的质量标准,以提高紫堇属药用植物的安全性和质量。本研究对紫堇属药用植物、紫堇属药用植物及相关标准进行总结,有望为紫堇属药材的标准制定、质量评价、扩大药源及合理开发利用提供参考。